Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, and CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a ...
A 40-year-old forgotten paper helped UChicago scientists develop a faster, more efficient method for synthesizing MXenes at a ...
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
In 2025, Adimab and its partners initiated discovery on 75 new therapeutic programs, bringing the total number of royalty-bearing programs commenced to more than 650. Many partners retain the ...
Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties Royalty Pharma maintained industry leadership ...
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine ...
A large genetic screen has revealed how stem cells transform into brain cells, exposing hundreds of genes that make this ...
Morning Overview on MSN
Ocean sugars can trigger cancer cells to self-destruct, study suggests
From the deep sea to the shallow seafloor, researchers are uncovering unusual sugars that do something extraordinary to ...
Venkatesan Sundaresan and Imtiyaz Khanday have already moved on to maize, millets. ‘What works with rice is potentially ...
The animals' camouflaging capabilities have long inspired humans. The new material could one day help researchers improve ...
While metabolomics is the large-scale comprehensive profiling of metabolites and other small molecules in the context of ...
About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback